Cancer Genetics Files to Raise up to $46M in Public Offering

Oct 09, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Cancer Genetics has filed to raise up to $46 million in a public offering of its stock.

The company, which went public in April, filed its Form S-1 with the US Securities and Exchange Commission on Tuesday. It has not priced its shares or said how many shares it plans to offer. In August, Cancer Genetics made a public offering of $15 million of its shares, and began trading on the Nasdaq.

Aegis is listed as the sole book-running agent on Tuesday's SEC filing.

During the second quarter, the Rutherford, NJ-based cancer diagnostics firm said revenues increased 64 percent year over year to $1.8 million. It ended the quarter with $1.9 million in cash and cash equivalents.

In afternoon trading shares of Cancer Genetics were down more than 17 percent at $15.51.

Filed under

Microarrays & Multiplexing

Cancer Genetics

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.